墨西哥东北部代谢综合征患者中 COVID-19 疫苗对 SARS-CoV-2 感染、住院和死亡的有效性评估：一项多中心研究
Assessment of COVID-19 Vaccine Effectiveness Against SARS-CoV-2 Infection, Hospitalization and Death in Mexican Patients with Metabolic Syndrome from Northeast Mexico: A Multicenter Study.
作者信息
Silva Ramírez Beatriz, Peñuelas Urquides Katia, Escobedo Guajardo Brenda Leticia, Mata Tijerina Viviana Leticia, Cruz Luna Jorge Eleazar, Corrales Pérez Roberto, Gómez García Salvador, González Escalante Laura Adiene, Camacho Moll María Elena
机构信息
Laboratory of Immunogenetics, Northeast Biomedical Research Center, Mexican Social Security Institute, Monterrey 64720, Nuevo Leon, Mexico.
Laboratory of Molecular Microbiology, Northeast Biomedical Research Center, Mexican Social Security Institute, Monterrey 64720, Nuevo Leon, Mexico.
出版信息
Vaccines (Basel). 2025 Feb 27;13(3):244. doi: 10.3390/vaccines13030244.
Metabolic syndrome (MetS) is a predisposing factor for severe COVID-19. The effectiveness of COVID-19 vaccines in patients with MetS has been poorly investigated. The aim of this study was to evaluate the effectiveness of COVID-19 vaccination before (BO) and after the Omicron (AO) SARS-CoV-2 variant in patients with MetS. This retrospective observational study was carried out in a total of 3194 patients with MetS and a COVID-19 PCR or rapid antigen test. The main outcomes were vaccine effectiveness against infection, hospitalization and death resulting from COVID-19. BO, only two doses of BNT162b2 were effective against infection, this effectiveness was lost AO. Also, with two doses, BNT162b2, ChAdOx1 and CoronaVac were effective against hospitalization BO; however, AO, only BNT162b2 and CoronaVac were effective. Regarding death as an outcome of COVID-19, two doses of BNT162b2 were effective BO, whereas AO, BNT162b2 and CoronaVac were 100% effective. BO the presentation of a sore throat increased after two doses of COVID-19 vaccine regardless of the type, and the presentation of dyspnea diminished after two doses of BNT162b2 and CoronaVac. The SARS-CoV-2 Omicron variant has impacted vaccines' effectiveness against hospitalization and death in patients with MetS. A tailored vaccination scheme for patients with MetS should be implemented due to the varying effectiveness rates observed in our study.
代谢综合征（MetS）是重症 COVID-19 的一个诱发因素。针对患有代谢综合征的患者接种 COVID-19 疫苗的有效性研究较少。本研究旨在评估 SARS-CoV-2 奥密克戎变异株出现之前（BO）和之后（AO），患有代谢综合征的患者接种 COVID-19 疫苗的有效性。这项回顾性观察研究共纳入了 3194 例患有代谢综合征且进行了 COVID-19 聚合酶链反应（PCR）或快速抗原检测的患者。主要观察指标为疫苗针对 COVID-19 感染、住院和死亡的有效性。在 BO 阶段，仅两剂 BNT162b2 对感染有效，而在 AO 阶段这种有效性丧失。同样，在 BO 阶段，两剂 BNT162b2、ChAdOx1 和科兴新冠疫苗对住院有效；然而，在 AO 阶段，只有 BNT162b2 和科兴新冠疫苗有效。关于作为 COVID-19 结局的死亡情况，两剂 BNT162b2 在 BO 阶段有效，而在 AO 阶段，BNT162b2 和科兴新冠疫苗的有效性为 100%。在 BO 阶段，无论何种类型的 COVID-19 疫苗，接种两剂后喉咙痛的症状都会增加，而接种两剂 BNT162b2 和科兴新冠疫苗后呼吸困难的症状会减轻。SARS-CoV-2 奥密克戎变异株影响了针对患有代谢综合征患者的疫苗预防住院和死亡的有效性。鉴于我们研究中观察到的不同有效率，应为患有代谢综合征的患者实施量身定制的疫苗接种方案。
Zotero 插件